TrialUnited European gastroenterology journal2023

Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial.

Julian Panés et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.